Pro Medicus (ASX:PME) share price sinks despite new deal

The Pro Medicus (ASX: PME) share price is a poor performer so far today, despite the company announcing a positive update. We take a look.

| More on:
falling healthcare asx share price Mesoblast capital raising

Image source: Getty Images

The Pro Medicus Limited (ASX: PME) share price is a poor performer so far on Thursday despite the company providing a positive update. In early morning trade, the health imaging company’s shares are fetching $40.05, down 1.26%.

What was announced?

Investors have been selling Pro Medicus shares regardless of the company’s announced contract win.

According to its release, Pro Medicus’ wholly-owned United Stated subsidiary, Visage Imaging Inc., has signed a deal with The University of Vermont Health Network Inc (UVM).

Under the agreement, Pro Medicus will deploy its Visage 7 Enterprise Imaging Platform across 6 hospitals operated by UVM. It is expected that, once the system is fully functional, a unified diagnostic imaging platform will run across the network. This replaces the existing multiple legacy PACS platforms that are currently being used.

The contract is valid for a period of 8 years and is estimated to generate $14 million in revenue for Pro Medicus.

Rollout of the system is scheduled to commence immediately, with go-live dates targeted for the second half of 2021. The Visage 7 platform will be deployed in the public cloud.

The company noted that the latest deal further expands its United States academic institution footprint. Pro Medicus believes that its transactional licensing model could also lead to further potential sales in the future.

Pro Medicus CEO Dr Sam Hupert commented:

We continue to build momentum in the market with this, our seventh contract win in a row, adding to other recent major announcements.

UVM Health Network is the fourth of these to opt for a cloud-based solution, a trend we see increasing rapidly amongst healthcare systems in North America.

Our pipeline continues to grow. Visage 7 with its proven cloud-native capability provides us with a significant strategic advantage that enables us to address these opportunities across a growing segment of the market both in North America and other regions.

Pro Medicus share price snapshot

Over the last 12 months, the Pro Medicus share price has stormed around 55% higher, with year to date performance delivering gains of around 17%. The company’s shares reached an all-time high of $48.69 last month.

Based on valuation grounds, Pro Medicus commands a market capitalisation of around $4.2 billion, with approximately 104 million shares outstanding.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A smiling woman looks at her computer laptop in her home with warm lights in the background feeling happy to see the EMvision share price rising
Healthcare Shares

EMvision share price rockets 11% on $5 million pay day

Shares in the Australian medical device company shot higher today.

Read more »

retirement investing represented by older investor looking concerned at computer screen
Healthcare Shares

Why is the Medibank share price struggling to gain ground in May?

We check what's going on with shares in the private health insurer.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Healthcare Shares

Here’s why the Imugene share price just got a boost

Imugene's latest announcement is rallying up investors.

Read more »

A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
Healthcare Shares

Why the AnteoTech share price is rocketing 33% today

What did AnteoTech update the ASX with?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Growth Shares

Why CSL shares are ‘going to deliver’ in 2022: fund manager

Quality growth companies can perform well even in an era of rising interest rates.

Read more »

a group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Incannex share price pops 9% on FDA news

The medicinal cannabis drug development company came out with some positive developments from its FDA meeting...

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Broker Notes

Where next for the CSL share price?

CSL shares could be heading higher according to one leading broker...

Read more »

A telehealth doctor at her desk.
Healthcare Shares

Why is the Ramsay share price smashing the ASX 200 on Monday?

Ramsay shares are off to a positive start today.

Read more »